Table 1.
SARS-CoV-2 infection (n = 200) | |
---|---|
Demographics | |
Age, y, median (IQR) | 40.6 (30.2–51.7) |
Male sex, n (%) | 58 (29.0) |
Ethnicity, n (%) | |
Caucasian | 163 (81.5) |
Hispanic | 13 (6.5) |
Mixed | 8 (4.0) |
African | 6 (3.0) |
Asian | 4 (2.0) |
Others | 2 (1.0) |
Not provided | 4 (2.0) |
Comorbidities, n (%) | |
Obesity (BMI ≥30) | 23 (11.5) |
Asthma | 17 (8.5) |
Hypertension | 9 (4.5) |
Cancera | 7 (3.5) |
Autoimmune diseaseb | 6 (3.0) |
Diabetes | 3 (1.5) |
Chronic lung diseasec | 3 (1.5) |
Eczema | 3 (1.5) |
Inflammatory bowel disease | 2 (1.0) |
Hepatic disease | 2 (1.0) |
Primary immune deficiency | 1 (0.5) |
Othersd | 4 (2.0) |
No past medical history | 140 (70.0) |
Habits, n (%) | |
Smoking | 23 (11.5) |
Vaping | 9 (4.5) |
Neither smoking nor vaping | 173 (86.5) |
BMI, body mass index; IQR, interquartile range.
Solid tumour (n = 5); leukaemia (n = 1); melanoma (n = 1).
Psoriasis (n = 2), hyperthydoidism (n = 1); hypothyroidism (n = 1); lupus (n = 1), ankylosing spondylitis (n = 1).
Chronic obstructive pulmonary disease (n = 1); emphysema (n = 1); pulmonary sarcoidosis (n = 1).
Endometriosis (n = 2); obstructive apnoea (n = 1); pacemaker (n = 1).